Author Login

Correspondence to Author: Olatunji BI (MD)^I , Olaleye OO (PHD)^II, McNeil RTO (PHD)^III. 

I * Department of Anatomy and Histology, Sefako Makgatho Health Science University, Ga-Rankuwa . Phone: 061 966 7054, Email: giftandjoy01@gmail. com.
11* Dept of Oral Biological Sciences, Faculty of Health sciences,University of the Witwatersrand Medical School, Johannesburg South Africa. Phone: 078 742 2147 Email: Olatunbosun.Olaleye@wits.ac.za
111* Department of Human Anatomy, Faculty of Basic Medical sciences, College of Medicine, University of Jos Nigeria. Phone: 071 975 9167. Email: rosiemcneil@gmail.com

DOI: 10.52338/joctr.2025.4896

Abstract:

Introduction:Some studies have suggested that Efavirenz may have anti-proliferative effects on various cancer cell lines, potentially through mechanisms that involve cell cycle arrest and inhibition of cell division. The aim of this work is to investigate the potential effects of efavirenz on cancer cells due to its ability to interfere with cellular processes.
Cal 27 cells are human oral squamous cell carcinoma of the tongue, a cell line commonly used in cancer research. These cells have a limited specific information available.
Aims and objectives: To evaluate the anti-mitotic effects of efavirenz on CAL 27 cell lines, and to determine the toxic concentration on efavirenz on the cells.
Methods: : Experimental groups were established with differing concentrations of the drugs, along with control groups. Cell viability was assessed 48 hours after treatment using a trypan blue assay, and the cells were harvested based on confluence criteria. Cell counting was done using an automated Luna-FL™ dual fluorescence cell counter. Data analysis was conducted using one-way Analysis of Variance (ANOVA) to compare drug efficacies, with a significance level set at 0.05 (p ≤ 0.05).
Results: Our data analysis revealed that EFV treatments did not exhibit significant main effects on the viability of the cancer cell line (F (6,20) = 0.7970; p =0.5878).
Discussion/Conclusion: Efavirenz is an antiretroviral drug commonly used to treat HIV-1 infection. Our results show anti-mitotic effects that suggest Efavirenz has potential as a therapeutic agent in the treatment of oral cancer, particularly in combination with other chemotherapeutic agents. However, further research is needed to enable us fully to understand its action mechanisms and grade its efficacy in this context.

Keywords:Cal 27 cells ; Efavirenz; anti-mitotic; oral squamous cell; anti-angiogenic; AIDS -defining cancers; anti proliferative; Apoptosis.

Citation:

Olatunji BI (MD), Anti-Mitotic Properties Of Efavirenz On Cal 27 Cell Line. Journal of Cancer and Tumor Research 2025.